Cargando…
盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察
BACKGROUND AND OBJECTIVE: Icotinib is the first self-developed small molecular drug in China for targeted therapy of lung cancer. Compared to the other two commercially available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib, icotinib is similar to them...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015183/ https://www.ncbi.nlm.nih.gov/pubmed/26706949 http://dx.doi.org/10.3779/j.issn.1009-3419.2015.12.04 |